What does the future hold for clinical trials? According to recent research, 70 – 80% of all trials will be hybrid, taking place at the site, local clinic, and in the patient’s home. This shift impacts sites, sponsors, and patients in unique ways, creating both challenges and opportunities.
Learn why clinical research is moving rapidly toward decentralized models and how to achieve success in this new hybrid era. In this webinar, you will hear from industry leaders Matthew McCarty, Madeline Geday, Juliet Hulse, and Gregory Tuyteleers as they discuss how to keep the patient experience front and center when designing decentralized clinical trials, including all the various factors that should be taken into consideration to achieve success.
- How decentralized trials increase patient choice and improve access
- How to overcome common patient challenges with decentralized trials
- How sites, sponsors, home health nurses, and patients can best work together
- How to integrate technology in ways that enhance the patient experience
Please fill out the following form to watch this webinar.
Global Lead, Decentralized Clinical Trials, Janssen R&D Global Development
Greg is the Global Lead for the decentralized trials program for Janssen Research & Development. In this role, he is responsible for leading the initiative that develops and implements the strategy and capabilities supporting decentralized trials. In addition, Greg is the Global Operations Head for Managed Access at Janssen. In that capacity, he is responsible for the operational management, execution, & oversight of managed access programs globally, which includes pre-approval access & post-trial access programs. Greg has been with Janssen since 2007 and has held various positions of increasing responsibility both in Commercial and R&D. Prior to joining Janssen, he worked as a consultant mainly supporting healthcare & technology companies.
Senior Director of Global Research Nurse Strategy and Patient Advocacy, Illingworth Research Group
Juliet joined Illingworth Research Group in 2011 as a Senior Research Nurse and after several promotions was appointed to her current position in 2020. Juliet has over 20 years of experience in clinical research, beginning her career in cardiology research covering Phase I-IV trials. More recently, she has specialized in neurology research in the field of multiple sclerosis (MS). Juliet has wide experience in the management of trial projects from initiation to closeout, as well as working with site investigators to improve patient recruitment and patient retention to the study protocols. She believes developing a strategy that places the patient in the center of the trial is vital for a successful study.
Senior Director, Head of Patient Engagement, ERT
Though new to ERT, Madeline has more than two decades of senior leadership experience and subject matter expertise within the pharmaceutical industry. After beginning her career as a clinical research associate, Madeline spent 17 years at Merck optimizing global trials and patient and stakeholder engagement as Director of Global Patient Engagement and Innovation, implementing patient-centric methodologies while increasing the diversity of patient representation. By continuing to incorporate the voice of the patient, Madeline provides strategic analysis, enhancement, innovation, and direction at ERT in the areas of patient and site experience, diversity of patient recruitment, health literacy, employee engagement, sales and marketing, and more.
Chief Marketing & Strategy Officer, ERT
Matt is responsible for defining and leading ERT’s strategy for providing customers with a holistic experience. Matt has spent the last 12 years leading teams and innovating products in both the clinical research and commercial healthcare settings to reduce the patient burden of participation and to support patients in their healthcare journey. Most recently, Matt was Global Head of Patient Engagement for ICON’s Commercialization & Outcomes division and, prior to that, Head of Direct-to-Patient Research (Virtual Trials) at IQVIA.